Miltenyi Biotec B.v. Co., Kg

Martin Meyer

Andrzej Dzionek

Ian Johnston

Wing Leung

Rafijul Bari

Iris Bürger

Markus Granzin

Thomas Schaser

Johann-Christoph Dettmann

The present invention provides the use of a packaging cell line for the production of VSV-G pseudotyped retroviral vector particles or virus like particles thereof, wherein said packaging cell line is negative for Low-Density Lipoprotein Receptor (LDLR), optionally said packaging cell line stably expresses VSV-G. A method for producing said VSV-G pseudotyped retroviral vector particles or virus like particles thereof is disclosed as well as said particles obtained by said method.

LDLR negative packaging cell line for the production of VSV-G pseudotyped retroviral vector particles or virus particles thereof

The present invention discloses a chimeric antigen receptor (CAR) comprising an antigen binding domain specific for BDCA2, a population of engineered cells expressing said CAR and a pharmaceutical composition thereof. Said engineered cells are for treatment of cancer in a subject, wherein the cancerous cells of said cancer express BDCA2 such as Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Chimeric antigen receptor specific for BDCA2 antigen

The present invention relates to polypeptides comprising a mutant human IgG, which mutant human IgGis capable of increasing the binding to and activation of immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing Fc&#x3b3;RIIb/c (CD32b), but not Fc&#x3b3;RIIa (CD32a). More specifically, the invention relates to polypeptides comprising at least one human IgGwith a lysine at position 409 (409K), using the EU index according to Kabat et al., which IgGis capable of binding to human CD32b/c with a statistically significant (p=0.05) higher binding affinity than a wild-type human IgGand than a wild-type human IgG, for use in the prevention and/or treatment of an autoimmune disease or allergy, as further defined in the claims.

Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303)

Growing community of inventors

Kürten, Germany

Martin Meyer